Synlogic Inc
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-system… Read more
Synlogic Inc (SYBX) - Net Assets
Latest net assets as of September 2025: $10.32 Million USD
Based on the latest financial reports, Synlogic Inc (SYBX) has net assets worth $10.32 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.55 Million) and total liabilities ($6.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.32 Million |
| % of Total Assets | 62.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -88.93% |
| 10-Year Change | -85.0% |
| Growth Volatility | 41.28 |
Synlogic Inc - Net Assets Trend (2013–2024)
This chart illustrates how Synlogic Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Synlogic Inc (2013–2024)
The table below shows the annual net assets of Synlogic Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $12.75 Million | -70.11% |
| 2023-12-31 | $42.66 Million | -48.37% |
| 2022-12-31 | $82.61 Million | -43.90% |
| 2021-12-31 | $147.27 Million | +27.91% |
| 2020-12-31 | $115.14 Million | -26.62% |
| 2019-12-31 | $156.91 Million | +26.44% |
| 2018-12-31 | $124.10 Million | +45.93% |
| 2017-12-31 | $85.04 Million | +40.90% |
| 2016-12-31 | $60.35 Million | -29.01% |
| 2015-12-31 | $85.02 Million | +277.30% |
| 2014-12-31 | $-47.95 Million | -60.30% |
| 2013-12-31 | $-29.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Synlogic Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41084700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.09% |
| Other Components | $454.39 Million | 3563.56% |
| Total Equity | $12.75 Million | 100.00% |
Synlogic Inc Competitors by Market Cap
The table below lists competitors of Synlogic Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turism Felix B
RO:TUFE
|
$2.73 Million |
|
NorthX Nickel Corp.
OTCQB:NXNIF
|
$2.73 Million |
|
ACMAT Corporation
PINK:ACMT
|
$2.73 Million |
|
Bowen Coking Coal Ltd
AU:BCB
|
$2.73 Million |
|
Lanakam S.A
AT:LANAC
|
$2.73 Million |
|
MM2 ASIA LTD
F:1MMA
|
$2.73 Million |
|
Stratabound Minerals Corp
OTCQB:SBMIF
|
$2.72 Million |
|
Richy Place 2002 Public Company Limited
BK:RICHY
|
$2.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Synlogic Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 42,655,000 to 12,751,000, a change of -29,904,000 (-70.1%).
- Net loss of 23,359,000 reduced equity.
- New share issuances of 22,000 increased equity.
- Other comprehensive income decreased equity by 6,000.
- Other factors decreased equity by 6,561,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.36 Million | -183.19% |
| Share Issuances | $22.00K | +0.17% |
| Other Comprehensive Income | $-6.00K | -0.05% |
| Other Changes | $-6.56 Million | -51.45% |
| Total Change | $- | -70.11% |
Book Value vs Market Value Analysis
This analysis compares Synlogic Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-26.41 | $0.67 | x |
| 2014-12-31 | $-42.33 | $0.67 | x |
| 2015-12-31 | $118.78 | $0.67 | x |
| 2016-12-31 | $20.28 | $0.67 | x |
| 2017-12-31 | $189.69 | $0.67 | x |
| 2018-12-31 | $77.94 | $0.67 | x |
| 2019-12-31 | $77.72 | $0.67 | x |
| 2020-12-31 | $48.19 | $0.67 | x |
| 2021-12-31 | $39.92 | $0.67 | x |
| 2022-12-31 | $17.28 | $0.67 | x |
| 2023-12-31 | $6.56 | $0.67 | x |
| 2024-12-31 | $1.05 | $0.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Synlogic Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -183.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -291987.50%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.55x
- Recent ROE (-183.19%) is below the historical average (-56.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.44 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.04 Million |
| 2015 | -29.39% | 0.00% | 0.00x | 1.07x | $-33.48 Million |
| 2016 | -43.52% | -5916.22% | 0.01x | 1.06x | $-32.30 Million |
| 2017 | -47.48% | -1652.09% | 0.02x | 1.17x | $-48.88 Million |
| 2018 | -39.03% | -1922.02% | 0.02x | 1.13x | $-60.84 Million |
| 2019 | -31.02% | -2188.44% | 0.01x | 1.20x | $-64.36 Million |
| 2020 | -49.10% | -10373.76% | 0.00x | 1.25x | $-68.05 Million |
| 2021 | -39.46% | -3313.45% | 0.01x | 1.19x | $-72.84 Million |
| 2022 | -80.07% | -5605.68% | 0.01x | 1.34x | $-74.41 Million |
| 2023 | -134.29% | -1699.26% | 0.04x | 1.77x | $-61.55 Million |
| 2024 | -183.19% | -291987.50% | 0.00x | 1.55x | $-24.63 Million |
Industry Comparison
This section compares Synlogic Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Synlogic Inc (SYBX) | $10.32 Million | 0.00% | 0.60x | $2.73 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |